Dublin, June 5, 2025 (GLOBE NEWSWIRE) — The “Artificial Intelligence in Pathology Market Report 2025” is now available from ResearchAndMarkets.com.
The market for artificial intelligence in pathology is undergoing robust growth, characterized by an in-depth evaluation of its features, size, and future growth prospects. The market size is projected to increase from $1.22 billion in 2024 to $1.39 billion in 2025, representing a compound annual growth rate (CAGR) of 13.8%. This growth is driven by factors such as the increasing prevalence of diseases, heightened funding, and rising demand for pathology services.
Future forecasts indicate continued expansion, with expectations for the market to reach $2.31 billion by 2029, at a CAGR of 13.5%. Factors fueling this growth include advancements in AI for clinical trials, improvements in healthcare infrastructure, interdisciplinary partnerships, and the development of AI-based predictive analytics. Noteworthy trends during this period encompass AI-enhanced diagnostic tools, integration with electronic health records, computer-aided diagnosis, AI-supported biomarker discovery, and genomic data amalgamation.
Personalized medicine plays a crucial role in market growth by enhancing AI’s significance in pathology. This method tailors treatments according to individual genetic backgrounds, lifestyles, and disease profiles, improving treatment effectiveness while minimizing side effects. Innovations powered by AI are advancing medical image analysis and genetic data interpretation, resulting in more accurate diagnoses and personalized treatment strategies.
Leading firms are innovating by introducing state-of-the-art solutions, such as advanced cancer detection systems that boost diagnostic precision and streamline processes. A notable example is Paige.ai’s launch of the Paige Lymph Node Module in March 2022, which assists pathologists in detecting breast cancer metastases with exceptional sensitivity, thereby improving both efficiency and accuracy.
Strategic partnerships and acquisitions play a vital role in shaping the market landscape. The acquisition of Crosscope by Clarapath in March 2023 reflects initiatives aimed at enhancing digital pathology platforms through advanced AI capabilities, which improve efficiency in pathology labs. Crosscope’s AI-empowered digital pathology imaging platform illustrates this strategic integration.
Notable companies in this market include F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., and Hamamatsu Photonics K.K., contributing to a competitive environment. Asia-Pacific emerged as the leading market in 2023, while North America is expected to exhibit the fastest growth during the forecast timeline.
